Monitoring Fondaparinux in the Setting of Antithrombin Deficiency.

Keywords

Fondaparinux, Medicine, Antithrombin, Heparin, Adverse effect

References

• Decision Making And Problem SolvingSachi Nandan Mohanty — 2014
• The Reduced Anticoagulant Effect of Fondaparinux at Low Antithrombin LevelsCarl‐Erik Dempfle, Julia Eichner, Nenad Suvajac — 2009
• Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study.Matthew Kang, Majed Alahmadi, Sonja Sawh — 2015
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.David García, Trevor Baglin, Jeffrey I. Weitz — 2012
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Jack Hirsh, Kenneth A. Bauer, Maria Benedetta Donati — 2008
• Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Lori‐Ann Linkins, Antonio L. Dans, Lisa K. Moores — 2012
• Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.Toshio Fukuda, Chikako Kamisato, Yuko Honda — 2013
• New antiplatelet drugs and new oral anticoagulants.V. Koenig-Oberhuber, Miodrag Filipovic — 2016
• Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States.Ahmed Aljabri, Yvonne Huckleberry, Jason H. Karnes — 2016
• Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case reportArturo Cafolla, Giuseppe Gentile — 2017
• Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patientsZhihao Zhang, Jingwen Zhang, He Ping — 2017
• Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.Marc Schindewolf, Julia Steindl, Jan Beyer‐Westendorf — 2017

Cited by

• HeparinJun — 2019
• Is fondaparinux safe for use during pregnancy? A state-of-the-art review of current evidenceYuexiao Wu, Yurou Ji, Siqi Wang — 2025
• An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and PerspectivesClaudiu Morgovan, Adina Frum, Laurențiu Stoicescu — 2026

Related papers

• Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy.Chirag Modi, Dhaval Satani, Kelly Cervellione — 2009
• Thrombosis due to Heparin-Induced Thrombocytopenia in Cardiac Surgery: is Fondaparinux an Effective Treatment?David Barillà, Gian Luca Martinelli — 2016
• PO-75 Efficacy and safety of fondaparinux in the management of strongly suspected heparin-induced thrombocytopenia (HIT): the key role of an early diagnosisStefano Barco, Marisa Barone, Chiara Beltrametti — 2010
• Elimination of Intravenously Administered Radiolabelled Antithrombin III and Heparin in Humansde Swart Ca, B Nijmeyer, Andersson Lo — 1984
• [Ten questions related to heparin-induced thrombocytopenia].Vincenzo Toschi — 2023
• Fondaparinux treatment of acute heparin‐induced thrombocytopenia confirmed by the serotonin‐release assay: a 30‐month, 16‐patient case seriesTheodore E. Warkentin, Menaka Pai, Jo‐Ann I. Sheppard — 2011
• Fondaparinux-Associated Heparin-Induced ThrombocytopeniaMicah Burch, Barry Cooper — 2012
• The heparin-catalysed inhibition of human factor XIa by antithrombin III is dependent on the heparin type.Hans Soons, Guido Tans, H.C. Hemker — 1988
• [Fondaparinux treatment in heparin induced thrombocytopenia:a case report].Savaş Özsu — 2011